The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
A Controlled Trial of Rasagiline in Early Parkinson Disease: The TEMPO Study
Open accessAbstract
CONTEXT: Monotherapy with rasagiline mesylate may be useful in early Parkinson disease (PD). OBJECTIVE: To evaluate the safety and efficacy of the selective monoamine oxidase type B inhibitor rasagiline. DESIGN: Multicenter, 26-week, parallel-group, randomized, double-blind, placebo-controlled clinical trial. SETTING: Academically based movement disorders clinics. PATIENTS: Patients with early PD not requiring dopaminergic therapy (n = 404). INTERVENTION: Research participants were randomized to rasagiline mesylate at dosages of 1 mg or 2 mg per day or matching placebo. A 1-week escalation period was followed by a 25-week maintenance period. MAIN OUTCOME MEASURE: The primary prespecified measure of efficacy was the change in the total Unified Parkinson's Disease Rating Scal score between baseline and 26 weeks of treatment, comparing each active treatment group with the placebo group. RESULTS: Monotherapy with rasagiline was effective in this 26-week study. The adjusted effect size for the total Unified Parkinson's Disease Rating Scale was -4.20 units comparing 1 mg of rasagiline and placebo (95% confidence interval, -5.66 to -2.73 units; P<.001) and -3.56 units comparing a 2-mg dosage and placebo (95% confidence interval, -5.04 to -2.08 units; P<.001). There were no meaningful differences in the frequency of adverse events or premature withdrawals among the treatment groups. CONCLUSIONS: Rasagiline is effective as monotherapy for patients with early PD. The 2 dosages in this trial were both effective relative to placebo. Further study is warranted to evaluate the longer-term effects of rasagiline in PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
An inventory for measuring depression
BECK, A. T. (1961) · Archives of General Psychiatry · doi:10.1001/archpsyc.1961.01710120031004 · Cited by 38,032
Parkinsonism: onset, progression, and mortality
Hoehn, M. M., & Yahr, M. D. (1967) · Neurology · doi:10.1212/wnl.17.5.427 · Cited by 12,107
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1976) · British Journal of Cancer · doi:10.1038/bjc.1976.220 · Cited by 2,294
Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's Disease
(1993) · New England Journal of Medicine · doi:10.1056/nejm199301213280305 · Cited by 1,221
Parkinsonism: Onset, progression, and mortality
Hoehn, M., & Yahr, M. (2011) · Neurology · doi:10.1212/01.wnl.0000405146.06300.91 · Cited by 1,061
Core assessment program for intracerebral transplantations (CAPIT)
Langston, J. W., Widner, H., Goetz, C. G., Brooks, D., Fahn, S., Freeman, T., & Watts, R. (1992) · Movement Disorders · doi:10.1002/mds.870070103 · Cited by 1,008
Effect of Deprenyl on the Progression of Disability in Early Parkinson's Disease
The Parkinson Study Group* (1989) · New England Journal of Medicine · doi:10.1056/nejm198911163212004 · Cited by 917
Shannon, K. M., Bennett, J. P., Friedman, J. H., & the Pramipexole Study Group (1997) · Neurology · doi:10.1212/wnl.49.3.724 · Cited by 281
Ropinirole for the treatment of early Parkinson's disease
Adler, C. H., Sethi, K. D., Hauser, R. A., Davis, T. L., Hammerstad, J. P., Bertoni, J., Taylor, R. L., Sanchez-Ramos, J., O'Brien, C. F., & Ropinirole Study Group (1997) · Neurology · doi:10.1212/wnl.49.2.393 · Cited by 281
Huang, W., Chen, Y., Shohami, E., & Weinstock, M. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00929-7 · Cited by 141
Effect of lazabemide on the progression of disability in early Parkinson's disease
Kieburtz (1996) · Annals of Neurology · doi:10.1002/ana.410400116 · Cited by 113
Carrillo, M. C., Minami, C., Kitani, K., Maruyama, W., Ohashi, K., Yamamoto, T., Naoi, M., Kanai, S., & Youdim, M. B. H. (2000) · Life Sciences · doi:10.1016/s0024-3205(00)00643-3 · Cited by 109
Abu‐Raya, S., Blaugrund, E., Trembovler, V., Bloch‐Shilderman, E., Shohami, E., & Lazarovici, P. (1999) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19991101)58:3<456::aid-jnr12>3.0.co;2-s · Cited by 89
Mechanism underlying anti-apoptotic activity of a (−)deprenyl-related propargylamine, rasagiline
Maruyama, W., Yamamoto, T., Kitani, K., Carrillo, M. C., Youdim, M. B. H., & Naoi, M. (2000) · Mechanisms of Ageing and Development · doi:10.1016/s0047-6374(00)00144-5 · Cited by 86
Effects of N-propargyl-1-(R)aminoindan (rasagiline) in models of motor and cognition disorders
Speiser, Z., Levy, R., & Cohen, S. (1998) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-6499-0_29 · Cited by 74
Heikkila, R. E., Duvoisin, R. C., Finberg, J. P. M., & Youdim, M. B. H. (1985) · European Journal of Pharmacology · doi:10.1016/0014-2999(85)90168-2 · Cited by 72
Factors Predictive of the Need for Levodopa Therapy in Early, Untreated Parkinson's Disease
McDermott, M., Jankovic, J. J., Carter, J., Fahn, S., Gauthier, S. G., Goetz, C. G., Golbe, L. I., Koller, W. C., Lang, A. E., Olanow, C. W., et al. (1995) · Archives of Neurology · doi:10.1001/archneur.1995.00540300037010 · Cited by 61
A controlled trial of lazabemide (RO19–6327) in untreated Parkinson's disease
Parkinson Study Group, & Kieburtz, K. D. (1993) · Annals of Neurology · doi:10.1002/ana.410330404 · Cited by 42
Cited by
Lees, A. J., Hardy, J., & Revesz, T. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60492-x · Cited by 1,956
Samii, A., Nutt, J. G., & Ransom, B. R. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16305-8 · Cited by 1,265
Autophagy and apoptosis dysfunction in neurodegenerative disorders
Ghavami, S., Shojaei, S., Yeganeh, B., Ande, S. R., Jangamreddy, J. R., Mehrpour, M., Christoffersson, J., Chaabane, W., Moghadam, A. R., Kashani, H. H., et al. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.10.004 · Cited by 1,039
Description of Parkinson's Disease as a Clinical Syndrome
FAHN, S. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07458.x · Cited by 977
The scientific and clinical basis for the treatment of Parkinson disease (2009)
Olanow, C. W., Stern, M. B., & Sethi, K. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a1d44c · Cited by 908
Metadata
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2002-12-01
- Volume
- 59
- Issue
- 12
- Pages
- 1937
- ISSN
- 0003-9942 (ISSN-L)
- OpenAlex
- W2595176684
- Cited by
- 579
- References
- 19
- FWCI
- 16.32
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.